Gå direkt till innehåll

Fakta om projektet

Ansvarig på SVA

porträtt på Ali
Ali Mirazimi Forskare, adjungerad professor Inst. för Laboratoriemedicin ali.mirazimi@sva.se 070-367 25 73




H2020, European Comission


2017 - 2022


To date, there is NO FDA approved vaccine against CCHF available. Due to the lack of Vaccine for this important disease has European Commission, H2020, dedicated a big project (CCHFVaccine) for developing a vaccine against CCHF. The CCHFVaccine project, has been built on the success of the CCH Fever project (FP7), which had focused on improving the knowledge of CCHFV, in general. The specific aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis.

The vaccine candidates developed within this project will not only be developed for human use but also for domestic animals in endemic and non-endemic areas.

To achieve this overall aim, an intensive work plan (based on the previous CCH Fever and EDENext project results) will be put in place with the following specific objectives:

  • Objective 1: to produce already available and promising vaccine candidates and also further establish new vaccine candidates for CCHFV for animal experimentation.
  • Objective 2: to bring several unique animal models into front line vaccine research and to implement a roadmap for animal model evaluation.
  • Objective 3: to validate and bring the most promising vaccine candidates to clinical trials .
  • Objective 4: to ensure that an immune mediated protection is adequately understood and that the candidate vaccine(s) can elicit an appropriate and protective immune response.
  • Objective 5: to establish a clinical trial road map and perform clinical trials at Phase I for the most promising platform. In addition ensure a strategy for the effective deployment, utilisation in resource-poor settings, field-deployment logistics and an evaluation of the predicted cost and affordability of the final vaccine products.
  • Objective 6: to widely publicise the project and its results to public health bodies, NGOs,outbreak management teams and develop an exploitation plan.

This is a Collaboration between us and 14 other institutes, including NIH/USA.


Senast uppdaterad : 2018-01-17